Search / Trial NCT00000772

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Ribavirin Didanosine Drug Therapy, Combination Acquired Immunodeficiency Syndrome Aids Related Complex

Description

Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT). Patients receive ddI alone for 4 weeks, followed by 8 weeks of combination ddI/ribavirin. Patients who complete the first 12 weeks without major toxicity may receive an additional 12 weeks of combination therapy on an optional basis. Patients are followed for 60 days after the last treatment visit.

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Stable maintenance or prophylaxis therapy for opportunistic infection, if such therapy was administered for at least 30 days prior to study entry.
  • Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis.
  • Fluconazole for mucosal candidiasis or cryptococcosis.
  • Acyclovir (up to 1.0 g/day).
  • Dapsone.
  • Ketoconazole.
  • Quinolones.
  • Tetracycline.
  • Vitamins and herbal therapies.
  • Antibiotics as clinically indicated.
  • Systemic corticosteroids for < 21 days for acute problems.
  • Regularly prescribed medications.
  • Patients must have:
  • HIV positivity by ELISA confirmed by Western blot.
  • CD4 count < 500 cells/mm3 within 30 days prior to study entry.
  • No active opportunistic infections requiring treatment (patients on stable maintenance and prophylaxis therapy for opportunistic infections for at least 30 days are permitted).
  • NOTE:
  • Enrollment of women is encouraged.
  • Prior Medication:
  • Allowed:
  • Prior stable maintenance or prophylaxis therapy for opportunistic infection, if administered for at least 30 days prior to study entry.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Concurrent rifampin or rifabutin.
  • Other anti-HIV drugs and investigational agents.
  • Biological response modifiers.
  • Ganciclovir or foscarnet.
  • Systemic cytotoxic chemotherapy.
  • Concurrent Treatment:
  • Excluded:
  • Concurrent radiation therapy other than limited localized therapy to the skin.
  • Patients with the following prior conditions are excluded:
  • History of peripheral neuropathy.
  • History of pancreatitis or active liver disease.
  • Prior Medication:
  • Excluded:
  • Prior ddI.
  • Ribavirin within 60 days prior to study entry.
  • AZT or ddC within 2 weeks prior to study entry.
  • Prior Treatment:
  • Excluded:
  • Transfusion within 2 weeks prior to study entry.
  • Active alcohol abuse.

Attachments

readout_NCT00000772_2024-03-05.pdf

4.5 MB

NCT00000772_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Boston, Massachusetts, United States

Minneapolis, Minnesota, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0